PODD stock stays on investors' radar owing to its solid progress with Omnipod 5 and robust potential in the diabetes market.

11 analysts have shared their evaluations of Insulet PODD during the recent three months, expressing a mix of bullish and ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Insulet (PODD – Research Report) today and set a price target of $305.00. The ...

Medical device maker Insulet convinced a jury that Korean rival EOFlow owes it $452 million in damages for stealing trade ...

A jury found that competitor EOFlow and former executives misappropriated trade secrets for Insulet’s Omnipod insulin pumps.

Insulet, an Acton medical device manufacturer, has been awarded $452 million in total damages by a federal jury.

The lawsuit revolved around Insulet's Omnipod tubeless insulin pump – used with continuous glucose monitors (CGMs) to create ...

In a report released today, Matthew Taylor from Jefferies assigned a Buy rating to Insulet (PODD – Research Report), with a price target of ...

The Massachusetts district court awarded Insulet a total of $452 million, including $170 million in compensation plus $282 ...

The company said it had restarted production of intravenous solutions on two lines in November, and added they were manufacturing 1-liter IV solution bags, the most commonly used size by hospitals and ...

Insulet (Nasdaq:PODD) announced that it successfully defended its intellectual property against EOFlow in U.S. federal court.